Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nab-paclitaxel

10 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE14101

12/04/2015

Phase I/II Study of BYL719 and Nab-Paclitaxel in Patients with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Treatment

ECOGGIS1505

11/17/2015

A Randomized Phase II Study of Perioperative Mfolfirinox versus Gemcitabine/NAB-PACLITAXEL as Therapy for Resectable Pancreatic Adenocarcinoma

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCBRE1543

09/30/2015

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

Treatment

VICCGI1507

06/16/2015

NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

Treatment

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

VICCGI1497

01/27/2015

A Multi-Institutional, Single-Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma

Treatment

VICCGI1417

12/17/2014

A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Treatment

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer